1. Knottnerus, SJ, Bleeker, JC, Wüst, RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord 2018; 19: 93–106.
Google Scholar | Crossref | Medline2. Wilcken, B, Wiley, V, Hammond, J, et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003; 348: 2304–2312.
Google Scholar | Crossref | Medline3. Villoria, JG, Pajares, S, López, RM, et al. Neonatal screening for inherited metabolic diseases in 2016. Semin Pediatr Neurol 2016; 23: 257–272.
Google Scholar | Crossref | Medline4. Ohls, RK, Maheshwari, A, Christensen, RD. Hematology, Immunology and Genetics. Neonatology Questions and Controversies. 3rd ed. Philadelphia, PA: Elsevier, 2019.
Google Scholar5. Lindner, M, Hoffmann, GF, Matern, D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010; 33: 521–526.
Google Scholar | Crossref | Medline6. Spiekerkoetter, U, Bastin, J, Gillingham, M, et al. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 2010; 33: 555–561.
Google Scholar | Crossref | Medline7. Merritt, JL, Norris, M, Kanungo, S. Fatty acid oxidation disorders. Ann Transl Med 2018; 6: 473.
Google Scholar | Crossref | Medline8. Andresen, BS, Olpin, S, Poorthuis, BJ, et al. Clear correlation of genotype with disease phenotype in very–long-chain Acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999; 64: 479–494.
Google Scholar | Crossref | Medline9. Isackson, PJ, Bennett, MJ, Lichter-Konecki, U, et al. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2008; 94: 422–427.
Google Scholar | Crossref | Medline10. Spiekerkoetter, U, Khuchua, Z, Yue, Z, et al. General mitochondrial trifunctional protein (TFP) deficiency as a result of either α-or β-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover. Pediatr Res 2004; 55: 190–196.
Google Scholar | Crossref | Medline11. Vockley, J, Marsden, D, McCracken, E, et al. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment – a retrospective chart review. Mol Genet Metab 2015; 116: 53–60.
Google Scholar | Crossref | Medline12. Gillingham, MB, Harding, CO, Schoeller, DA, et al. Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder. Am J Physiol Endocrinol Metab 2013; 305: E1299–E1308.
Google Scholar | Crossref | Medline13. Lindner, M, Gramer, G, Haege, G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases – report of 10 years from South-West Germany. Orphanet J Rare Dis 2011; 6: 44.
Google Scholar | Crossref | Medline14. Spiekerkoetter, U, Lindner, M, Santer, R, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009; 32: 498–505.
Google Scholar | Crossref | Medline15. Spiekerkoetter, U, Lindner, M, Santer, R, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 2009; 32: 488–497.
Google Scholar | Crossref | Medline16. Gillingham, MB, Connor, WE, Matern, D, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab 2003; 79: 114–123.
Google Scholar | Crossref | Medline17. Arnold, GL, Van Hove, J, Freedenberg, D, et al. A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2009; 96: 85–90.
Google Scholar | Crossref | Medline18. Baruteau, J, Sachs, P, Broué, P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis 2013; 36: 795–803.
Google Scholar | Crossref | Medline19. Ultragenyx Pharmaceutical . Dojolvi triheptanoin oral liquid, 2020, https://www.dojolvi.com/
Google Scholar20. Ultragenyx Pharmaceutical . Dojolvi (Triheptanoin) oral liquid full prescribing information, 2020, https://www.ultragenyx.com/medicines/dojolvi-full-prescribing-information/
Google Scholar21. Shirley, M . Triheptanoin: first approval. Drugs 2020; 80: 1595–1600.
Google Scholar | Crossref | Medline22. Ultragenyx Pharmaceutical . Dojolvi triheptanoin oral liquid, 2021, https://www.ultragenyx.com/file.cfm/137/docs/Dojolvi_Final_PM_Clean.pdf
Google Scholar23. Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children [Press release] . 2021.
Google Scholar24. Ultragenyx announces approval of Dojolvi® (triheptanoin) in Brazil for the treatment of long-chain fatty acid oxidation disorders in adults and children [press release] . 23 August 2021.
Google Scholar25. Vockley, J, Burton, B, Berry, G, et al. UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24 weeks of treatment. Mol Genet Metab 2017; 120: 370–377.
Google Scholar | Crossref | Medline26. Vockley, J, Burton, B, Berry, GT, et al. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis 2019; 42: 169–177.
Google Scholar | Crossref | Medline27. Bennett, MJ, Rinaldo, P, Strauss, AW. Inborn errors of mitochondrial fatty acid oxidation. Crit Rev Clin Lab Sci 2000; 37: 1–44.
Google Scholar | Crossref | Medline28. Yamada, K, Taketani, T. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency. J Hum Genet 2019; 64: 73–85.
Google Scholar | Crossref | Medline29. Hunter, NL, O’Callaghan, KM, Califf, RM. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA 2015; 314: 2499–2500.
Google Scholar | Crossref | Medline30. Wilson, IB, Cleary, PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995; 273: 59–65.
Google Scholar | Crossref | Medline31. Immonen, T, Turanlahti, M, Paganus, A, et al. Earlier diagnosis and strict diets improve the survival rate and clinical course of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr 2016; 105: 549–554.
Google Scholar | Crossref | Medline32. US Food and Drug Administration . Developing and submitting proposed draft guidance relating to patient experience data: guidance for industry and other stakeholders (Draft Guidance), 2018, https://www.fda.gov/media/119542/download
Google Scholar33. Gater, A, Tatlock, S, Arbuckle, R. Listening to the patient: the application and value of qualitative research for gathering patient insights during drug development and evaluation. Qual Life Res 2019; 28: S6–S7.
Google Scholar34. US Food and Drug Administration . Patient-focused drug development: methods to identify what is important to patients. guidance for industry, Food and Drug Administration Staff, and other stakeholders (Draft Guidance), 2019, https://www.fda.gov/media/131230/download
Google Scholar35. Brédart, A, Marrel, A, Abetz-Webb, L, et al. Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients’ experience. Health Qual Life Out 2014; 12: 15.
Google Scholar | Crossref | Medline36. ATLAS.ti. Scientific Software Development GmbH . Atlas.ti.software (Version 7). Berlin: ATLAS.ti.ScientificSoftware Development GmbH, 2013.
Google Scholar37. Braun, V, Clarke, V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77–101.
Google Scholar | Crossref38. Benjamin, K, Vernon, MK, Patrick, DL, et al. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA Emerging Good Practices Task Force report. Value Health 2017; 20: 838–855.
Google Scholar | Crossref | Medline39. US Food and Drug Administration . Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders, 2020, https://www.fda.gov/media/139088/download
Google Scholar40. Waisbren, SE, Landau, Y, Wilson, J, et al. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev 2013; 17: 260–268.
Google Scholar | Crossref | Medline41. Laforet, P, Acquaviva-Bourdain, C, Rigal, O, et al. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 2009; 19: 324–329.
Google Scholar | Crossref | Medline42. Donatti, C, Wild, D, Hareendran, A. The use of conceptual models, conceptual frameworks, and endpoint models to support label claims of treatment benefit using patient reported outcomes. ISPOR Connect 2008; 14: 9–12.
Google Scholar43. Vockley, J, Charrow, J, Ganesh, J, et al. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab 2016; 119: 223–231.
Google Scholar | Crossref | Medline44. Spiekerkoetter, U . Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 2010; 33: 527–532.
Google Scholar | Crossref | Medline45. Goetzman, ES . Advances in the understanding and treatment of mitochondrial fatty acid oxidation disorders. Curr Genet Med Rep 2017; 5: 132–142.
Google Scholar | Crossref | Medline